ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 04/27/2011

ClinicalTrials.gov ID: NCT00494481

Study Identification

Unique Protocol ID:	D4200C00046
Brief Title:	E3 Breast Cancer Taxotere Combination
Official Title:	A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
Secondary IDs:	

Study Status

Record Verification:	April 2011
Overall Status:	Completed
Study Start:	January 2006
Primary Completion:	June 2007 [Actual]
Study Completion:	January 2009 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes

	Delayed Posting? No
IND/IDE Protocol?:	No
Review Board:	Approval Status: Approved Approval Number: M05/09/040 Board Name: Committee of Pharmaceutical Trials Board Affiliation: Stellenbosch University Phone: +27 21 938 9075 Email:
Data Monitoring?:	No
Plan to Share Data?:	
Oversight Authorities:	South Africa: Medicines Control Council Taiwan: Department of Health Sweden: Medical Products Agency Hungary: National Institute of Pharmacy Spain: Spanish Agency of Medicines

Study Description

Brief Summary:	To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Detailed Description:	

Conditions

Conditions:	Advanced Breast Cancer
Keywords:	Zactima

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	2
Masking:	Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)

Allocation:	Randomized
Endpoint Classification:	Safety/Efficacy Study
Enrollment:	64 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Placebo Comparator: 1 Docetaxel + placebo vandetanib	Drug: Docetaxel intravenous infusion Other Names: • Taxotere®
Experimental: 2 Vandetanib + Docetaxel	Drug: Vandetanib (ZD6474) once daily oral dose Other Names: • ZACTIMA™ Drug: Docetaxel intravenous infusion Other Names: • Taxotere®

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age:	18 Years
Maximum Age:	
Gender:	Female
Accepts Healthy Volunteers?:	No
Criteria:	Inclusion Criteria:

- Females with histological/cytological confirmation of breast cancer.
- Subjects with a measurable lesion or bone lesions

Exclusion Criteria:

- Previous radiotherapy within 6 weeks

- Significant cardiac events, arrhythmias or other cardiac conditions

Contacts/Locations

Study Officials: Peter Langmuir, MD
Study Director
AstraZeneca

Locations: Hungary
Research Site
Budapest, Hungary

Research Site
Pécs, Hungary

South Africa
Research SIte
Bloemfontein, South Africa

Research Site
Cape Town, South Africa

Research Site
Observatory, South Africa

Spain
Research Site
Zaragoza, Spain

Research SIte
Lérida, Spain

Research Site
Baracaldo, Spain

Sweden
Research Site
Umeå, Sweden

Research Site
Uppsala, Sweden

Research Site
Västerås, Sweden

Taiwan
Research Site
Taipei, Taiwan

References

Citations:

Links: URL: http://www.astrazeneca.com/node/emailtriage.aspx
Description AstraZeneca Clinical Trial Information - Outside US

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	First patient randomised 03 February 2006, last patient randomised 25 April 2007, data cut off data 23 June 2007

Reporting Groups

	Description
Vandetanib Plus Docetaxel	vandetanib 100 mg plus docetaxel
Placebo Plus Docetaxel	placebo plus docetaxel

Overall Study

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
Started	35 [1]	29 [1]
Completed	6 [2]	5 [2]
Not Completed	29	24
Condition under investigation worsened	11	13
Adverse Event	15	11
Other	1	0
Never received IP	2	0

[1] randomised patients
[2] ongoing study treatment at data cut-off

Baseline Characteristics

Reporting Groups

	Description
Vandetanib Plus Docetaxel	vandetanib 100 mg plus docetaxel
Placebo Plus Docetaxel	placebo plus docetaxel

Baseline Measures

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel	Total
Number of Participants	35	29	64
Age, Continuous [units: Years] Mean (Full Range)	54 (33 to 80)	57 (39 to 74)	55.5 (33 to 80)
Gender, Male/Female [units: Participants]			
Female	35	29	64
Male	0	0	0

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Number of Patients With a Disease Progression Event
Measure Description	Number of patients with objective disease progression or death (by any cause in the absence of objective progression)
Time Frame	RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off
Safety Issue?	No

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
Vandetanib Plus Docetaxel	vandetanib 100 mg plus docetaxel
Placebo Plus Docetaxel	placebo plus docetaxel

Measured Values

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
Number of Participants Analyzed	35	29
Number of Patients With a Disease Progression Event [units: Participants]	24	18

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	[Not specified]

Reporting Groups

	Description
Vandetanib Plus Docetaxel	vandetanib 100 mg plus docetaxel
Placebo Plus Docetaxel	placebo plus docetaxel

Serious Adverse Events

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Total	14/33 (42.42%)	12/29 (41.38%)
Blood and lymphatic system disorders		
Febrile Neutropenia [A] †	3/33 (9.09%)	1/29 (3.45%)
Granulocytopenia [A] †	0/33 (0%)	1/29 (3.45%)
Neutropenia [A] †	4/33 (12.12%)	2/29 (6.9%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Cardiac disorders		
Atrial Fibrillation [A] †	1/33 (3.03%)	1/29 (3.45%)
Ear and labyrinth disorders		
Vertigo [A] †	1/33 (3.03%)	0/29 (0%)
Eye disorders		
Keratitis [A] †	1/33 (3.03%)	0/29 (0%)
Gastrointestinal disorders		
Colitis [A] †	0/33 (0%)	1/29 (3.45%)
Diarrhoea [A] †	3/33 (9.09%)	0/29 (0%)
Ileus [A] †	1/33 (3.03%)	0/29 (0%)
Nausea [A] †	1/33 (3.03%)	0/29 (0%)
Stomatitis [A] †	1/33 (3.03%)	0/29 (0%)
General disorders		
Asthenia [A] †	1/33 (3.03%)	0/29 (0%)
Fatigue [A] †	1/33 (3.03%)	0/29 (0%)
Pyrexia [A] †	0/33 (0%)	1/29 (3.45%)
Infections and infestations		
Cellulitis [A] †	1/33 (3.03%)	0/29 (0%)
Neutropenic Sepsis [A] †	0/33 (0%)	2/29 (6.9%)
Pharyngitis Streptococcal [A] †	0/33 (0%)	1/29 (3.45%)
Pneumonia [A] †	1/33 (3.03%)	1/29 (3.45%)
Tooth Abscess [A] †	0/33 (0%)	1/29 (3.45%)
Metabolism and nutrition disorders		

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Hypokalaemia [A] †	1/33 (3.03%)	0/29 (0%)
Nervous system disorders		
Vocal Cord Paralysis [A] †	0/33 (0%)	1/29 (3.45%)
Respiratory, thoracic and mediastinal disorders		
Dyspnoea [A] †	0/33 (0%)	3/29 (10.34%)
Hydrothorax [A] †	0/33 (0%)	1/29 (3.45%)
Skin and subcutaneous tissue disorders		
Dermatitis Exfoliative [A] †	1/33 (3.03%)	0/29 (0%)
Rash Papular [A] †	1/33 (3.03%)	0/29 (0%)
Toxic Epidermal Necrolysis [A] †	1/33 (3.03%)	0/29 (0%)
Vascular disorders		
Deep Vein Thrombosis [A] †	0/33 (0%)	1/29 (3.45%)
Hypertension [A] †	1/33 (3.03%)	0/29 (0%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 10.0

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Total	33/33 (100%)	25/29 (86.21%)
Blood and lymphatic system disorders		
Agranulocytosis [A] †	2/33 (6.06%)	2/29 (6.9%)
Anaemia [A] †	6/33 (18.18%)	6/29 (20.69%)
Febrile Neutropenia [A] †	3/33 (9.09%)	0/29 (0%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Leukopenia [A] †	10/33 (30.3%)	8/29 (27.59%)
Lymphopenia [A] †	3/33 (9.09%)	2/29 (6.9%)
Neutropenia [A] †	15/33 (45.45%)	13/29 (44.83%)
Thrombocytopenia [A] †	4/33 (12.12%)	0/29 (0%)
Ear and labyrinth disorders		
Vertigo [A] †	2/33 (6.06%)	1/29 (3.45%)
Eye disorders		
Conjunctivitis [A] †	2/33 (6.06%)	3/29 (10.34%)
Lacrimation Increased [A] †	2/33 (6.06%)	7/29 (24.14%)
Vision Blurred [A] †	0/33 (0%)	2/29 (6.9%)
Gastrointestinal disorders		
Abdominal Pain [A] †	6/33 (18.18%)	5/29 (17.24%)
Cheilitis [A] †	1/33 (3.03%)	3/29 (10.34%)
Constipation [A] †	5/33 (15.15%)	2/29 (6.9%)
Diarrhoea [A] †	13/33 (39.39%)	12/29 (41.38%)
Dry Mouth [A] †	4/33 (12.12%)	1/29 (3.45%)
Dyspepsia [A] †	3/33 (9.09%)	3/29 (10.34%)
Flatulence [A] †	2/33 (6.06%)	1/29 (3.45%)
Gastritis [A] †	2/33 (6.06%)	2/29 (6.9%)
Mouth Ulceration [A] †	0/33 (0%)	2/29 (6.9%)
Nausea [A] †	9/33 (27.27%)	10/29 (34.48%)
Odynophagia [A] †	2/33 (6.06%)	0/29 (0%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Stomatitis [A] †	16/33 (48.48%)	12/29 (41.38%)
Vomiting [A] †	3/33 (9.09%)	6/29 (20.69%)
General disorders		
Asthenia [A] †	3/33 (9.09%)	8/29 (27.59%)
Face Oedema [A] †	1/33 (3.03%)	2/29 (6.9%)
Fatigue [A] †	11/33 (33.33%)	7/29 (24.14%)
Influenza Like Illness [A] †	1/33 (3.03%)	2/29 (6.9%)
Malaise [A] †	2/33 (6.06%)	0/29 (0%)
Oedema Peripheral [A] †	7/33 (21.21%)	6/29 (20.69%)
Performance Status Decreased [A] †	2/33 (6.06%)	0/29 (0%)
Pyrexia [A] †	5/33 (15.15%)	3/29 (10.34%)
Infections and infestations		
Herpes Zoster [A] †	0/33 (0%)	2/29 (6.9%)
Nasopharyngitis [A] †	2/33 (6.06%)	1/29 (3.45%)
Oral Candidiasis [A] †	1/33 (3.03%)	2/29 (6.9%)
Pharyngitis [A] †	2/33 (6.06%)	3/29 (10.34%)
Upper Respiratory Tract Infection [A] †	0/33 (0%)	3/29 (10.34%)
Urinary Tract Infection [A] †	2/33 (6.06%)	0/29 (0%)
Injury, poisoning and procedural complications		
Alanine Aminotransferase Increased [A] †	2/33 (6.06%)	2/29 (6.9%)
Aspartate Aminotransferase Increased [A] †	2/33 (6.06%)	2/29 (6.9%)
Blood Alkaline Phosphatase Increased [A] †	2/33 (6.06%)	1/29 (3.45%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Chemical Eye Injury [A] †	2/33 (6.06%)	2/29 (6.9%)
Weight Decreased [A] †	3/33 (9.09%)	2/29 (6.9%)
Metabolism and nutrition disorders		
Anorexia [A] †	7/33 (21.21%)	9/29 (31.03%)
Musculoskeletal and connective tissue disorders		
Arthralgia [A] †	3/33 (9.09%)	2/29 (6.9%)
Back Pain [A] †	1/33 (3.03%)	2/29 (6.9%)
Bone Pain [A] †	0/33 (0%)	4/29 (13.79%)
Musculoskeletal Chest Pain [A] †	2/33 (6.06%)	0/29 (0%)
Musculoskeletal Pain [A] †	1/33 (3.03%)	2/29 (6.9%)
Myalgia [A] †	10/33 (30.3%)	9/29 (31.03%)
Pain In Extremity [A] †	2/33 (6.06%)	3/29 (10.34%)
Nervous system disorders		
Dizziness [A] †	3/33 (9.09%)	2/29 (6.9%)
Dysgeusia [A] †	5/33 (15.15%)	4/29 (13.79%)
Headache [A] †	4/33 (12.12%)	4/29 (13.79%)
Hypoaesthesia [A] †	4/33 (12.12%)	3/29 (10.34%)
Lethargy [A] †	3/33 (9.09%)	3/29 (10.34%)
Neurotoxicity [A] †	2/33 (6.06%)	1/29 (3.45%)
Paraesthesia [A] †	4/33 (12.12%)	9/29 (31.03%)
Peripheral Sensory Neuropathy [A] †	6/33 (18.18%)	3/29 (10.34%)
Psychiatric disorders		
Depression [A] †	2/33 (6.06%)	1/29 (3.45%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Insomnia [A] †	3/33 (9.09%)	2/29 (6.9%)
Renal and urinary disorders		
Dysuria [A] †	2/33 (6.06%)	1/29 (3.45%)
Reproductive system and breast disorders		
Vaginal Discharge [A] †	0/33 (0%)	2/29 (6.9%)
Respiratory, thoracic and mediastinal disorders		
Cough [A] †	8/33 (24.24%)	3/29 (10.34%)
Dyspnoea [A] †	6/33 (18.18%)	4/29 (13.79%)
Epistaxis [A] †	4/33 (12.12%)	0/29 (0%)
Pharyngolaryngeal Pain [A] †	5/33 (15.15%)	1/29 (3.45%)
Rhinorrhoea [A] †	2/33 (6.06%)	1/29 (3.45%)
Skin and subcutaneous tissue disorders		
Acne [A] †	3/33 (9.09%)	1/29 (3.45%)
Alopecia [A] †	17/33 (51.52%)	11/29 (37.93%)
Dermatitis Acneiform [A] †	3/33 (9.09%)	4/29 (13.79%)
Dry Skin [A] †	5/33 (15.15%)	5/29 (17.24%)
Erythema [A] †	7/33 (21.21%)	4/29 (13.79%)
Nail Discolouration [A] †	3/33 (9.09%)	0/29 (0%)
Nail Disorder [A] †	2/33 (6.06%)	2/29 (6.9%)
Nail Pigmentation [A] †	3/33 (9.09%)	3/29 (10.34%)
Onycholysis [A] †	6/33 (18.18%)	1/29 (3.45%)
Palmar-Plantar Erythrodysaesthesia Syndrome [A] †	3/33 (9.09%)	0/29 (0%)

	Vandetanib Plus Docetaxel	Placebo Plus Docetaxel
	Affected/At Risk (%)	Affected/At Risk (%)
Pigmentation Disorder [A] †	2/33 (6.06%)	0/29 (0%)
Rash [A] †	2/33 (6.06%)	1/29 (3.45%)
Rash Erythematous [A] †	1/33 (3.03%)	3/29 (10.34%)
Rash Maculo-Papular [A] †	5/33 (15.15%)	0/29 (0%)
Rash Pruritic [A] †	2/33 (6.06%)	0/29 (0%)
Skin Exfoliation [A] †	2/33 (6.06%)	5/29 (17.24%)
Skin Hyperpigmentation [A] †	3/33 (9.09%)	3/29 (10.34%)
Vascular disorders		
Flushing [A] †	2/33 (6.06%)	2/29 (6.9%)
Hot Flush [A] †	0/33 (0%)	2/29 (6.9%)
Hypertension [A] †	5/33 (15.15%)	0/29 (0%)
Lymphoedema [A] †	0/33 (0%)	2/29 (6.9%)

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 10.0

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between the Principal Investigator and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Official Title: Gerard Lynch

Organization: AstraZeneca
Phone:
Email: aztrial_results_posting@astrazeneca.com